Fusion Antibodies plc

Default features description for sign up page.

Updates

Regulatory News

Company Presentations

Webinars

Board Profiles

Company Profile

Home

Fusion Deep Dive

Advisers

Company Information & FAQs

Corporate Governance

Share Price

New investors

Shareholder Information

Raleway

In this episode, CEO Adrian Kinkaid offers a deep dive into how Fusion Antibodies has strategically navigated post-pandemic market challenges. Over the past few years, Fusion's focus on VC-funded biotech companies developing therapeutic antibodies was impacted by rising interest rates, leading to a move toward the diagnostics market. Adrian shares how this shift allowed Fusion to tap into the booming diagnostics industry, where their expertise in antibody development was in high demand, especially during the pandemic.

Adrian also explains how Fusion overcame initial hurdles in connecting with diagnostics companies, leveraging their scientific credibility and engaging directly at industry events. This approach has paid off, resulting in strong uptake and ongoing projects with both small and large diagnostics companies. Looking ahead, Adrian emphasises Fusion’s commitment to deepening these relationships and expanding their footprint in the diagnostics sector.

We’d love to hear your thoughts and questions about Fusion’s journey and future strategies. Submit your questions through the 'Ask a Question' button, and our management team will be happy to provide insights and answers. Engage with us and stay informed about what’s next for Fusion Antibodies!

Navigating Post-Pandemic Challenges: Fusion Antibodies' Resilience and Future Outlook